RETROVIR, a drug licensed in Britain for treating people with AIDS or
other symptoms of infection with HIV, may soon be available for treating
people with HIV who have shown no sign of illness. The Wellcome Foundation,
the British pharmaceuticals company, announced this week that it had won
provisional clearance from the Committee for Proprietary Medicinal Products
of the European Commission to seek wider use for Retrovir. Individual member
states of the EC are now considering the committee’s recommendations.
More from New Scientist
Explore the latest news, articles and features
Environment
Evocative photos of Canadian Arctic win New Scientist Editors Award
Regulars
Environment
June heatwave may have killed around 20,000 people in Europe
News
Physics
Random wobbles in time could finally solve gravity’s greatest mystery
News
Life
Synthetic biology may finally be ready to solve life's biggest mystery
Leader
Popular articles
Trending New Scientist articles
1
Random wobbles in time could finally solve gravity’s greatest mystery
2
June heatwave may have killed around 20,000 people in Europe
3
Humans sleep the least of all apes – is it the secret to our success?
4
A type of fibre that stimulates GLP-1 release approved for use in food
5
The world's fastest spider tops 3.5 metres per second
6
The 4 must-watch science-fiction films of the year so far
7
The weirdness of neutrinos could completely rewrite particle physics
8
The best new science-fiction novels published in July 2026
9
What is 'SpudCell'? Arguably the greatest bioengineering feat yet
10
Synthetic biology may finally be ready to solve life's biggest mystery
